ID

35618

Description

Study ID: 111611 Clinical Study ID: 111611 Study Title: A randomised, double-blind, placebo-controlled study to assess the effect of oral, single dose SB-705498 in a validated intranasal capsaicin challenge model in healthy volunteers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00731250 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: SB-705498, Placebo, Caspaicin Trade Name: N/A Study Indication: Rhinitis

Keywords

  1. 3/12/19 3/12/19 -
Copyright Holder

GSK group of companies

Uploaded on

March 12, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

The effect of intranasal capsaicin challenge model in healthy volunteers - 111611

Follow-Up

  1. StudyEvent: ODM
    1. Follow-Up
Administrative data
Description

Administrative data

Date of Visit
Description

Date of Visit

Data type

date

STATUS OF TREATMENT BLIND
Description

STATUS OF TREATMENT BLIND

Was the treatment blind broken during the study?
Description

If Yes, complete the Adverse Event Form and/or Investigational Product forms as appropriate

Data type

boolean

Date blind broken
Description

Date Blind Broken

Data type

date

Reason blind broken
Description

Reason Blind Broken

Data type

text

If Other, please specify
Description

Specify Other

Data type

text

STUDY CONCLUSION
Description

STUDY CONCLUSION

Date of subject completion or withdrawal
Description

Date of completion or withdrawal

Data type

date

Was the subject withdrawn from the study?
Description

subject withdrawal

Data type

boolean

Reasons for withdrawal
Description

Mark primary reason only

Data type

text

If Investigator discretion, specify
Description

Investigator discretion, specify

Data type

text

PREGNANCY INFORMATION
Description

PREGNANCY INFORMATION

Did the subject become pregnant during the study?
Description

Pregnancy during the Study

Data type

boolean

Did a female partner of the male subject become pregnant during the study?
Description

Pregnancy of a Partner during the Study

Data type

text

Adverse Event/Concomitant Medications/Repeat Assessment (Check Questions)
Description

Adverse Event/Concomitant Medications/Repeat Assessment (Check Questions)

Were any concomitant medications taken by the subject during the study?
Description

Concomitant Medication

Data type

boolean

Did the subject experience any non-serious adverse events during the study?
Description

Non-Serious Adverse Events

Data type

boolean

Did the subject experience any serious adverse events during the study?
Description

Serious Adverse Events

Data type

boolean

Were any abnormal, clinically significant ECG measurements recorded for this subject during the study?
Description

Clinically Significant ECG Measurements

Data type

boolean

Were any repeat hematology or clinical chemistry samples taken?
Description

Repeat Hematology/ Clinical Chemistry

Data type

boolean

Were any repeat ECGs performed?
Description

Repeat ECGs

Data type

boolean

Were any repeat vital signs or temperature measurements recorded?
Description

Repeat Vital Signs / Temperature

Data type

boolean

Were any repeat PK blood samples taken?
Description

Repeat PK Blood Samples

Data type

boolean

Were any repeat Peak Nasal Inspiratory Flow tests performed?
Description

Repeat Peak Nasal Inspiratory Flow Tests

Data type

boolean

NON-SERIOUS ADVERSE EVENTS
Description

NON-SERIOUS ADVERSE EVENTS

Event Number
Description

Event Number

Data type

integer

Event Description
Description

Diagnosis or Signs/Symptoms

Data type

text

Start Date and Time
Description

Start Date and Time

Data type

datetime

End Date and Time
Description

End Date and Time

Data type

datetime

Outcome
Description

Outcome

Data type

text

Frequency
Description

Frequency

Data type

text

Maximum Intensity
Description

Maximum Intensity

Data type

text

Action Taken with Investigational Product(s) as a result of the AE?
Description

Action Taken

Data type

text

Did the subject withdraw from study as a result of this AE?
Description

Subject Withdrawal

Data type

boolean

Is there a reasonable possibility tha the AE may have been caused by the investigational product?
Description

Causality

Data type

boolean

SERIOUS ADVERSE EVENTS
Description

SERIOUS ADVERSE EVENTS

SAE Number
Description

SAE Number

Data type

integer

Serious Adverse Event Description
Description

Diagnosis or Sighs/Symptoms

Data type

text

Start Date and Time
Description

Start Date and Time

Data type

datetime

End Date and Time
Description

End Date and Time

Data type

datetime

Outcome
Description

Outcome

Data type

text

Maximum Intensity
Description

Maximum Intensity

Data type

text

Action Taken with Investigational Product(s) as a Result of the SAE
Description

Action Taken

Data type

text

Did the subject withdraw from the study as a result of this SAE?
Description

Subject Withdrawn

Data type

boolean

Is there a reasonable possibility tha the AE may have been caused by the investigational product?
Description

Causality

Data type

boolean

Was SAE cause by activities related to study participation(e.g. procedures)?
Description

Was SAE study related?

Data type

boolean

Was the event serious
Description

Seriousness of Event

Data type

boolean

How serious was the SAE?
Description

SAE Seriousness Level

Data type

text

If Other, please specify
Description

Specify Other

Data type

text

Did SAE occur after initiation of study medication?
Description

SAE Occurrence after study initiation

Data type

boolean

Type of Report
Description

Type of Report

Data type

text

RELEVANT CONCOMITANT/TREATMENT MEDICATIONS
Description

RELEVANT CONCOMITANT/TREATMENT MEDICATIONS

Drug/Medication sequence number
Description

Drug/Medication sequence number

Data type

integer

Drug Name
Description

Trade name preferred

Data type

text

Dose
Description

Dose

Data type

text

Unit
Description

Unit

Data type

text

Frequency
Description

Frequency

Data type

text

Route
Description

Route

Data type

text

Start Date
Description

Start Date

Data type

date

Ongoing?
Description

Ongoing?

Data type

boolean

Primary Indication
Description

Primary Indication

Data type

text

RELEVANT MEDICAL CONDITION/RISK FACTORS
Description

RELEVANT MEDICAL CONDITION/RISK FACTORS

Condition number
Description

Condition number

Data type

integer

Specific Condition Name
Description

Specific Condition Name

Data type

text

Date of onset
Description

Start Date

Data type

date

Ongoing?
Description

Ongoing?

Data type

text

Date of last occurrence
Description

End Date

Data type

date

Relevant Medical History / Risk Factors not noted above
Description

Medical History

Data type

text

RELEVANT DIAGNOSTIC RESULTS
Description

RELEVANT DIAGNOSTIC RESULTS

Lab sequence number
Description

Lab sequence number

Data type

integer

Test Name
Description

Test Name

Data type

text

Test Date
Description

Test Date

Data type

date

Test Result
Description

Test Result

Data type

text

Test Unit
Description

Test Unit

Data type

date

Comment
Description

Comment

Data type

text

INVESTIGATIONAL PRODUCTS
Description

INVESTIGATIONAL PRODUCTS

If investigational product(s) stopped, did the reported event(s) recur after further investigational product(s) were administered?
Description

Investigational Product Stopped

Data type

text

GENERAL NARRATIVE COMMENTS
Description

GENERAL NARRATIVE COMMENTS

Provide a brief narrative description of SAE, possible other causes of the event (e.g. lack of efficacy, withdrawal of investigational product, the disease under study or other medical condition) and details of the treatment.
Description

General narrative comments

Data type

text

Provide a brief narrative description of SAE, possible other causes of the event (e.g. lack of efficacy, withdrawal of investigational product, the disease under study or other medical condition) and details of the treatment.
Description

General Narrative Comments

Data type

text

Similar models

Follow-Up

  1. StudyEvent: ODM
    1. Follow-Up
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative data
Date of Visit
Item
Date of Visit
date
Item Group
STATUS OF TREATMENT BLIND
Status of Treatment Blind
Item
Was the treatment blind broken during the study?
boolean
Date Blind Broken
Item
Date blind broken
date
Item
Reason blind broken
text
Code List
Reason blind broken
CL Item
medical emergency requiring identification of investigational product for further treatment (1)
CL Item
Other (2)
Specify Other
Item
If Other, please specify
text
Item Group
STUDY CONCLUSION
Date of completion or withdrawal
Item
Date of subject completion or withdrawal
date
subject withdrawal
Item
Was the subject withdrawn from the study?
boolean
Item
Reasons for withdrawal
text
Code List
Reasons for withdrawal
CL Item
Adverse Event (1)
CL Item
Protocol Violation (2)
CL Item
Subject reached protocol defined stopping criteria (3)
CL Item
Study closed / terminated (4)
CL Item
Lost to Follow-up (5)
CL Item
Investigator discretion (6)
CL Item
Withdrew consent (7)
Investigator discretion, specify
Item
If Investigator discretion, specify
text
Item Group
PREGNANCY INFORMATION
Pregnancy during the Study
Item
Did the subject become pregnant during the study?
boolean
Item
Did a female partner of the male subject become pregnant during the study?
text
Code List
Did a female partner of the male subject become pregnant during the study?
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not Applicable (if female partner not of childbearing potential or no female partner) (3)
Item Group
Adverse Event/Concomitant Medications/Repeat Assessment (Check Questions)
Concomitant Medication
Item
Were any concomitant medications taken by the subject during the study?
boolean
Non-Serious Adverse Events
Item
Did the subject experience any non-serious adverse events during the study?
boolean
Serious Adverse Events
Item
Did the subject experience any serious adverse events during the study?
boolean
Clinically Significant ECG Measurements
Item
Were any abnormal, clinically significant ECG measurements recorded for this subject during the study?
boolean
Repeat Hematology/ Clinical Chemistry
Item
Were any repeat hematology or clinical chemistry samples taken?
boolean
Repeat ECGs
Item
Were any repeat ECGs performed?
boolean
Repeat Vital Signs / Temperature
Item
Were any repeat vital signs or temperature measurements recorded?
boolean
Repeat PK Blood Samples
Item
Were any repeat PK blood samples taken?
boolean
Repeat Peak Nasal Inspiratory Flow Tests
Item
Were any repeat Peak Nasal Inspiratory Flow tests performed?
boolean
Item Group
NON-SERIOUS ADVERSE EVENTS
Event Number
Item
Event Number
integer
Event Description
Item
Event Description
text
Start Date and Time
Item
Start Date and Time
datetime
End Date and Time
Item
End Date and Time
datetime
Item
Outcome
text
Code List
Outcome
CL Item
Recovered/Resolved  (1)
CL Item
Recovering/Resolving (2)
CL Item
Not recovered/not resolved (3)
CL Item
Recovered/Resolved with sequelae (4)
Item
Frequency
text
Code List
Frequency
CL Item
Single episode (1)
CL Item
Intermittent (2)
Item
Maximum Intensity
text
Code List
Maximum Intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
CL Item
Not applicable (4)
Item
Action Taken with Investigational Product(s) as a result of the AE?
text
Code List
Action Taken with Investigational Product(s) as a result of the AE?
CL Item
Investigational Product(s) withdrawn (1)
CL Item
Dose reduced (2)
CL Item
Dose increased (3)
CL Item
Dose not changed (4)
CL Item
Dose interrupted (5)
CL Item
Not applicable (6)
Subject Withdrawal
Item
Did the subject withdraw from study as a result of this AE?
boolean
Causality
Item
Is there a reasonable possibility tha the AE may have been caused by the investigational product?
boolean
Item Group
SERIOUS ADVERSE EVENTS
SAE Number
Item
SAE Number
integer
SAE Description
Item
Serious Adverse Event Description
text
Start Date and Time
Item
Start Date and Time
datetime
End Date and Time
Item
End Date and Time
datetime
Item
Outcome
text
Code List
Outcome
CL Item
Recovered/Resolved  (1)
CL Item
Recovering/Resolving (2)
CL Item
Not recovered/not resolved (3)
CL Item
Recovered/Resolved with sequelae (4)
Item
Maximum Intensity
text
Code List
Maximum Intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
CL Item
Not applicable (4)
Item
Action Taken with Investigational Product(s) as a Result of the SAE
text
Code List
Action Taken with Investigational Product(s) as a Result of the SAE
CL Item
Investigational Product(s) withdrawn (1)
CL Item
Dose reduced (2)
CL Item
Dose increased (3)
CL Item
Dose not changed (4)
CL Item
Dose interrupted (5)
CL Item
Not applicable (6)
Subject Withdrawn
Item
Did the subject withdraw from the study as a result of this SAE?
boolean
Causality
Item
Is there a reasonable possibility tha the AE may have been caused by the investigational product?
boolean
Was SAE study related?
Item
Was SAE cause by activities related to study participation(e.g. procedures)?
boolean
Seriousness of Event
Item
Was the event serious
boolean
Item
How serious was the SAE?
text
Code List
How serious was the SAE?
CL Item
results in death (1)
CL Item
is life-threatening (2)
CL Item
requires hospitalisation or prolongation of existing hospitalisation (3)
CL Item
results in disability/incapacity (4)
CL Item
congenital anomaly/birth defect (5)
CL Item
Other (6)
Specify Other
Item
If Other, please specify
text
SAE Occurrence after study initiation
Item
Did SAE occur after initiation of study medication?
boolean
Item
Type of Report
text
Code List
Type of Report
CL Item
Initial (1)
CL Item
Follow-Up (2)
Item Group
RELEVANT CONCOMITANT/TREATMENT MEDICATIONS
Drug/Medication sequence number
Item
Drug/Medication sequence number
integer
Drug Name
Item
Drug Name
text
Dose
Item
Dose
text
Item
Unit
text
Code List
Unit
CL Item
Actuation (1)
CL Item
Ampoule (2)
CL Item
Application (3)
CL Item
Bottle (4)
CL Item
Capsule (5)
CL Item
Cubic centimeter (6)
CL Item
Drops (7)
CL Item
Gram (8)
CL Item
International Units (9)
CL Item
International Units per kilogram (10)
CL Item
International Units per millilitre (11)
CL Item
Litre (12)
CL Item
Litre per minute (13)
CL Item
lozenge (14)
CL Item
Megaunits (million units) (15)
CL Item
Megaunits (MCG) (16)
CL Item
Megaunits (UG) (17)
CL Item
Microgram/kilogram (18)
CL Item
Microgram/kilogram per minute (19)
CL Item
Migrograms per minute (20)
CL Item
Microlitre (21)
CL Item
Milliequvalent (22)
CL Item
Milliequvalent per 24 hours (23)
CL Item
Milligram (24)
CL Item
Milligrams percent (25)
CL Item
Milligram per hour (26)
CL Item
Milligram/kilogram (27)
CL Item
Milligram/kilogram per hour (28)
CL Item
Milligram/kilogram per minute (29)
CL Item
Milligram/metre squared (30)
CL Item
Milligram/millilitre (31)
CL Item
Millilitre (32)
CL Item
Millilitre per hour (33)
CL Item
Millilitre per minute (34)
CL Item
Millimole (35)
CL Item
Million international units (36)
CL Item
Minimum alveolar concentration (37)
CL Item
Nebule (38)
CL Item
Patch (39)
CL Item
Percent (40)
CL Item
Puff (41)
CL Item
Sachet (42)
CL Item
Spray (43)
CL Item
Suppository (44)
CL Item
Tablespoon (45)
CL Item
Tablet (46)
CL Item
Teaspoon (47)
CL Item
Units (48)
CL Item
Unknown (49)
CL Item
Vial (50)
Item
Frequency
text
Code List
Frequency
CL Item
2 times per week (1)
CL Item
3 times per week (2)
CL Item
4 times per week (3)
CL Item
5 times per day (4)
CL Item
5 times per week (5)
CL Item
AC (6)
CL Item
BID (7)
CL Item
Continuous infusion (8)
CL Item
Every 2 weeks (9)
CL Item
Every 3 weeks (10)
CL Item
Every 3 months (11)
CL Item
Every other day (12)
CL Item
At bedtime (13)
CL Item
Once a month (14)
CL Item
Once a week (15)
CL Item
Once daily (16)
CL Item
Once only (17)
CL Item
PC (18)
CL Item
PRN (19)
CL Item
Q2H (20)
CL Item
Q3D (21)
CL Item
Q4D (22)
CL Item
Q4H (23)
CL Item
Q6H (24)
CL Item
Q8H (25)
CL Item
Q12H (26)
CL Item
QAM (27)
CL Item
QH (28)
CL Item
QID (29)
CL Item
QPM (30)
CL Item
TIO (31)
CL Item
Unknown (32)
Item
Route
text
Code List
Route
CL Item
Both eyes (1)
CL Item
Epidural (2)
CL Item
Gastrostomy tube (3)
CL Item
Inhalation (4)
CL Item
Injection (5)
CL Item
Intra-arterial (6)
CL Item
Intra-bursa (7)
CL Item
Intralesional (8)
CL Item
Intramuscular (9)
CL Item
Intranasal (10)
CL Item
Intraocular (11)
CL Item
Intraosteal (12)
CL Item
Intraperitoneal (13)
CL Item
Intrathecal (14)
CL Item
Intrauterine (15)
CL Item
Intravenous (16)
CL Item
Nasal (17)
CL Item
Oral (18)
CL Item
Rectal (19)
CL Item
Subcutaneous (20)
CL Item
Sublingual (21)
CL Item
Topical (22)
CL Item
Transdermal (23)
CL Item
Unknown (24)
CL Item
Vaginal (25)
Start Date
Item
Start Date
date
Ongoing?
Item
Ongoing?
boolean
Primary Indication
Item
Primary Indication
text
Item Group
RELEVANT MEDICAL CONDITION/RISK FACTORS
Condition number
Item
Condition number
integer
Specific Condition Name
Item
Specific Condition Name
text
Start Date
Item
Date of onset
date
Item
Ongoing?
text
Code List
Ongoing?
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown (3)
End Date
Item
Date of last occurrence
date
Medical History
Item
Relevant Medical History / Risk Factors not noted above
text
Item Group
RELEVANT DIAGNOSTIC RESULTS
Lab sequence number
Item
Lab sequence number
integer
Item
Test Name
text
Code List
Test Name
CL Item
Activated partical tromboplastin time (1)
CL Item
Albumin (2)
CL Item
Alkaline phosphatase (3)
CL Item
Amylase (4)
CL Item
Basophils (5)
CL Item
Bicarbonate (6)
CL Item
Bilirubin (7)
CL Item
Bilirubin direct (8)
CL Item
Bilirubin total (9)
CL Item
Blood myoglobin (10)
CL Item
Blood pH (11)
CL Item
Blood Pressure (12)
CL Item
Blood urea nitrogen (13)
CL Item
Body temperature (14)
CL Item
Calcium (15)
CL Item
CD4 Lymphocytes (16)
CL Item
CD8 lymphocytes (17)
CL Item
Chloride (18)
CL Item
Cholesterol total (19)
CL Item
C-reactive protein (20)
CL Item
Creatine (21)
CL Item
Creatine phosphokinase (22)
CL Item
Creatine phosphokinase MB (23)
CL Item
Creatinine (24)
CL Item
Creatinine clearance (25)
CL Item
Diastolic blood pressure (26)
CL Item
Eosinophils (27)
CL Item
Erithrocyte sedimentation rate (28)
CL Item
Fasting blood glucose (29)
CL Item
FEV 1 (30)
CL Item
Gamma-glutamyltransferase (31)
CL Item
Glutamic-oxaloacetic transaminase (32)
CL Item
Glutamic-pyruvate transaminase (33)
CL Item
HbA1c (34)
CL Item
HBV-DNA decreased (35)
CL Item
HBV-DNA increased (36)
CL Item
Heart rate (37)
CL Item
Hematocrit (38)
CL Item
Hemoglobin (39)
CL Item
High density lipoprotein (40)
CL Item
HIV viral load (41)
CL Item
INR (42)
CL Item
Lactic dehydrogenase (43)
CL Item
Lipase (44)
CL Item
Low density lipoprotein (45)
CL Item
Lymphocytes (46)
CL Item
Magnesium (47)
CL Item
Mean cell hemoglobin concentration (48)
CL Item
Mean corpuscular hemoglobin (49)
CL Item
Mean corpuscular volume (50)
CL Item
Monocytes (51)
CL Item
Neutrophils (52)
CL Item
Oxygen saturation (53)
CL Item
pCO2 (54)
CL Item
pH (55)
CL Item
Phosphate (56)
CL Item
Palatelet count (57)
CL Item
pO2 (58)
CL Item
Potassium (59)
CL Item
Protein total (60)
CL Item
Prothrombin time (61)
CL Item
Red blood cell count (62)
CL Item
Respiratory rate (63)
CL Item
Reticulocyte count (64)
CL Item
Serum glucose (65)
CL Item
Serum uric acid (66)
CL Item
Sodium (67)
CL Item
Systolic blood pressure (68)
CL Item
Thrombin time (69)
CL Item
Total lung capacity (70)
CL Item
Triglycerides (71)
CL Item
Troponin (72)
CL Item
Troponin 1 (73)
CL Item
Troponin T (74)
CL Item
Urine myoglobin (75)
CL Item
Urine pH (76)
CL Item
Vital capacity (77)
CL Item
White blood cell count (78)
Test Date
Item
Test Date
date
Item
Test Result
text
Code List
Test Result
Test Unit
Item
Test Unit
date
Comment
Item
Comment
text
Item Group
INVESTIGATIONAL PRODUCTS
Item
If investigational product(s) stopped, did the reported event(s) recur after further investigational product(s) were administered?
text
Code List
If investigational product(s) stopped, did the reported event(s) recur after further investigational product(s) were administered?
CL Item
No (1)
CL Item
Yes (2)
CL Item
Unknown at this time (3)
CL Item
Not applicable (4)
Item Group
GENERAL NARRATIVE COMMENTS
General narrative comments
Item
Provide a brief narrative description of SAE, possible other causes of the event (e.g. lack of efficacy, withdrawal of investigational product, the disease under study or other medical condition) and details of the treatment.
text
General Narrative Comments
Item
Provide a brief narrative description of SAE, possible other causes of the event (e.g. lack of efficacy, withdrawal of investigational product, the disease under study or other medical condition) and details of the treatment.
text

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial